Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule belonging to the phenylpyrazole class, with the molecular formula C20H23N5O and a molecular weight of approximately 349.4 g/mol. It is an experimental agent that has not been approved for any therapeutic use. The primary known mechanism of action is inhibition of the proto-oncogene tyrosine-protein kinase Src (SRC), a non-receptor tyrosine kinase involved in cellular signaling pathways related to proliferation, differentiation, and survival. There are no reported clinical indications or approvals for this compound, and it appears to be used primarily as a research tool in biochemical studies targeting SRC[2][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-phenylurea.